Summary: Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United States and can be classified on the basis of various pathologic, molecular, and genetic features, including microsatellite instability (MSI). As MSI is generally associated with a more favorable outcome in colorectal cancers, it is feasible that microsatellite instability may also influence endometrial cancer survival. We examined MSI and survival in 45 African American and 31 white women diagnosed with endometrial cancer at a large, urban cancer center. Fifty-five tumors were classified as type I and 21 tumors were classified as type II. Unconditional logistic regression models found that microsatellite stable tumors were more frequently observed in white women compared with African American women (odds ratio, 8.61; 95% confidence interval, 1.01-73.69). Type I tumors with MSI were not found to be significantly associated with smoking status, tumor stage, or age. Only one type II tumor was classified as MSI. Neither race nor MSI status was a predictor of death from all causes or only endometrial cancer-related deaths were considered in univariate and multivariate survival models. The potential significance of a larger proportion of MSI tumors found in African American women with type I endometrial cancer should be assessed in a larger prospective study. Key Words: Endometrial neoplasms-Microsatellite instability-African Americans.
Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United States, with an estimated 42,160 new cases and 7780 deaths in 2009 (1) . Of particular concern, the death rate from endometrial cancer, after declining in earlier decades, has remained largely unchanged since the early 1990s (1) . Endometrial cancers can be broadly grouped into 2 main subtypes. Of the 2 clinicopathologic subtypes, type I (endometrioid) is associated with unopposed estrogen exposure, greater incidence relative to type II (serous and clear cell cancers), high level of differentiation, and favorable prognosis. In contrast, type II tumors are characterized by estrogen independence, lower incidence, poor level of differentiation, aggressive clinical course, and worse prognosis (2, 3) .
In addition to being categorized by subtype, endometrial cancers can also be classified on the basis of genetic features. Microsatellites are repetitive sequences of DNA, consisting of 1 to 4 nucleotides. Microsatellite instability (MSI) results when insertions or deletions occur in these repeat sequences (4) .
Tumors exhibiting length polymorphisms are classified as MSI, whereas those lacking expansion or contraction of repeat sequences are classified as microsatellite stable (MSS) (5) . MSI in colorectal cancers is caused by abnormalities in DNA mismatch repair genes, mainly MLH1, MSH2, and MSH6 (6) .
In colorectal cancers, MSI has been positively correlated with proximal location of the tumor, poor differentiation, large tumor size, and improved prognosis (7) (8) (9) . As MSI is associated with a more favorable outcome in colorectal cancers, it is feasible that MSI, which is reported in 11% to 45% of endometrial cancers, may also influence endometrial cancer survival (10) . Evidence of MSI as a prognostic factor is varied for endometrial cancer, with some reports linking MSI with improved survival (11) (12) (13) and others with a worse prognosis (14, 15, 16) .
Another consideration is the potential interaction between MSI, race, and survival. The racial disparity in endometrial cancer survival rates between African American and white women has been noted (17) (18) (19) (20) . African American women have consistently shown to experience a less favorable outcome compared with white women, even after accounting for disease stage, tumor histology, tumor grade, and treatment course (18, 21, 22) . This study examines the relationships between MSI, race, and survival outcome from a single institution. Specifically, we assess whether MSI occurs more frequently in tumors from African American women, and whether this may partially explain the poorer prognosis seen in this population.
METHODS

Data Collection
Institutional approval was obtained from both the Wayne State University and the University of Michigan before the initiation of data collection. Women with a primary diagnosis of endometrial cancer from 1998 to 2006 who received a hysterectomy were identified retrospectively and randomly selected from the Pathology Department of Wayne State University. The following variables were abstracted from the medical records: name, date of birth, date of diagnosis, age at diagnosis, race, and smoking status. These data were then linked to the Metropolitan Detroit Cancer Surveillance System, part of the Surveillance, Epidemiology and End Results program, to gather additional information on stage at diagnosis, grade, histological type, vital status, months of survival, and cause(s) of death. The final linkage to update survival was performed on June 1, 2009. Uniform pathologic review was performed by 2 board certificated gynecologic pathologists (R.A.F. and K.R.C.) to confirm the diagnosis of invasive carcinoma of the uterus and to identify areas of tumor for DNA microdissection (areas with 470% cellularity were selected for microdissection). Tumors were then categorized as type I (endometrioid) or type II (serous and clear cell) for analytical purposes (23) . Mixed tumors were classified as type II tumors if they contained 410% serous component.
DNA Extraction
Paraffin-embedded tumor samples were obtained and ten 5-m-thick recut tissue slides were created. DNA from normal surrounding tissues (uninvolved cervical tissue in early-stage disease, uninvolved ovary in advanced-stage disease) and tumor tissue was extracted from unstained sections using standard methods.
MSI
MSI was determined by analysis of DNA derived from paired normal and tumor samples using a panel of 10 markers (5), including the consensus panel of 5 microsatellite markers developed initially for evaluation of colorectal cancer (BAT25, BAT26, D2S123, D5S346, D17S250) that have also been applied to the analysis of endometrial cancer (24) . Microsatellite marker loci were amplified by 3 multiplex polymerase chain reactions (PCRs) as follows: (1) D10S197, BAT26, b-catenin; (2) D18S58, BAT40, D2S123; and (3) D17S250, BAT25, TGF-b-RIIF, D5S346F. All 3 PCRs were performed using the same conditions: 10 minutes at 951C followed by 3 cycles at 951C for 1 minute, 571C for 1 minute, 721C for 1.5 minutes, and then 40 cycles at 951C for 1 minutes, 511C for 1 minute, 721C for 1.5 minutes, and completed at 721C for 10 minutes. The PCR fragments were detected by capillary electrophoresis on ABI370 at the University of Michigan Sequencing Core. The chromatograms were analyzed using GeneMarker v1.51 software (SoftGenetics, LLC., State College, PA). The patterns of the microsatellite markers in normal and tumor tissues were compared to find changes in the length of the markers. A tumor was considered to be MSI if Z30% of markers showed instability. Tumors with o30% of instable markers were considered MSI-low, and tumors with no instable markers were considered MSS. For analytical purposes, MSI-low 67 MSI AND ENDOMETRIAL CANCER SURVIVAL (6 individuals) and MSS tumors were combined and referred below as MSS.
Statistical Methods
Statistical analyses were performed using SAS version 9.1 (Cary, NC). The relationship between histological type and other clinical or demographic variables was assessed using w 2 tests or the Fisher exact test when o25% of the cells had counts o5. Unconditional logistic regression models were created to examine the association between MSI status and clinical and demographic variables. Survival time was calculated as number of days from the date of diagnosis until the date of last follow-up or death. Death was further stratified based on whether the primary or underlying cause of death mentioned endometrial cancer. Univariate survival analysis was performed using the Kaplan-Meier method. Survival analysis was also performed using Cox regression models to adjust for various prognostic variables. Statistical significance was defined as Po0.05 and all tests were 2-sided.
RESULTS
The study population consisted of 76 patients with endometrial carcinoma (55 type I, 21 type II), with African American women representing 59.2% of the population. Figure 1 shows representative photomicrographs of type I (Fig. 1A ) and type II (Fig. 1B) tumors. The clinical and pathologic features of the endometrial cancer cases are summarized in Table 1 . Women with type I tumors were more likely to be diagnosed in earlier stages and with low-grade tumors compared with women with type II tumors (both P values o0.0001), and women with type I tumors had longer survival times (P ¼ 0.001). Tumor type was not found to be associated with age, race, or smoking status. There were no differences in mean age at diagnosis between African American and white women in this sample (P ¼ 0.38, data not shown).
MSI was found in 11 (15%) of the endometrial tumors. Representative images of unstable markers are shown in Figure 2 . To determine whether there was a relationship between MSI status and other clinicopathologic features, data were stratified by type ( 
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as the odds ratio could not be calculated due to the small sample size. Kaplan-Meier univariate survival analysis was conducted to determine the prognostic value of certain clinical and pathologic features (Table 3) . Both categories of ''all deaths'' and ''endometrial cancer-related deaths'' were considered as end points. When evaluating all deaths, age, tumor stage, and histologic subtype were all found to be significant predictors (P ¼ 0.002, 0.0001, and o0.0001, respectively). However, when considering endometrial cancer-related deaths alone, age did not reach statistical significance (P ¼ 0.06), whereas tumor stage and type continued to hold prognostic value (P ¼ 0.002 and o0.0001, respectively). Among the endometrial cancer-related deaths, race approached statistical significance in predicting survival outcomes (P ¼ 0.06).
In the Cox multivariate survival analysis of all causes of death, older age (460 yr) was associated with poor survival in comparison with younger patients (o60 yr) (hazard ratio [HR], 2.42; 95% CI, 1.01-5.78) ( Table 4 ). In addition, type II tumors were 
DISCUSSION
The aim of this study was to determine whether MSI status is associated with race and/or survival in a single institution with a large number of African American patients. In our study cohort, there was a significant association between MSI status and race in women with type I tumors, with MSI tumors more prevalent in African American patients. Previous studies have noted a lack of association between MSI and race (11, 13, 22, 25) . Failure to detect the observed association between MSI and race in some studies may be explained by the fact that data were not stratified according to type (11, 25) . Nevertheless, in one study that did control for type, there was no correlation between MSI and race (13) . In contrast to our findings, another study of 229 endometrial cancers reported MSI being more common among whites, even after controlling for histologic subtype and disease stage (24) .
In our small cohort of women, MSI was not found to be of significant prognostic value. Previous studies have reported mixed results with regard to the association between MSI and survival. A number of studies parallel our present findings of no association (24) (25) (26) . Recently, a large study of 446 endometrial tumors failed to detect any association between survival and MSI status when only endometrioidtype tumors were examined (26) . In contrast, some reports have linked MSI with improved survival (11) (12) (13) , and others reported those with MSI tumors had a worse prognosis (14) (15) (16) . Although mixed results seem to be common among studies examining MSI and survival in endometrial cancers, the relationship is better established for colorectal cancers. MSI is the hallmark of deficient mismatch repair in colorectal cancers, and most of the observed mismatch repair deficiency in colorectal cancer in those over the age of 50 years at diagnosis is attributable to hypermethylation of MLH1, whereas germline mutations in mismatch repair genes are more common in patients with the age of 50 years of less at diagnosis (27) . In patients with Lynch syndrome, instability is not only observed in the colon but also at extracolonic sites, with endometrial cancer being the most common extracolonic malignancy (28) (29) (30) . Several studies have shown an association of MSI and improved survival among colorectal cancer patients with Lynch syndrome (31) (32) (33) . It is still unknown whether women with Lynch syndrome and endometrial cancer are more likely to have MSI tumors and improved survival compared with sporadic endometrial cancers. In our study, family history of endometrial or other cancers was not uniformly available from the medical records. For the 7 individuals diagnosed before the age of 50 years, 4 individuals had no family history of cancer noted, 2 had a family history of breast cancer in a first-degree relative, and 1 had no information. There was no mention of colorectal cancer in family members of these cases, suggesting that these cases are likely not Lynch syndrome related. (6) . Other studies used as few as 2 (15) or 3 markers (12,13), and as many as 8 markers (16), all defining MSI as the presence of instability in at least 2 of the markers.
In addition to having multiple definitions of MSI, the use of different cohorts may also contribute to the variance observed in the literature. Each study cohort varied in the proportion of tumors from African American women compared with white women. In our study, the ratio was near 1:1, with African American women representing 60% of our total study population. Another factor that may help to explain differences in all studies is that many, including ours, were unable to classify the cancer as sporadic or familial. Therefore, it becomes difficult to assess whether differences in survival are truly a result of defective DNA mismatch repair or some secondary effect of a familial cancer syndrome.
Our study has notable strengths, including the use of an equal ratio of tumors from white women and African American women, all seen at the same institution. Tumor histology was also assessed independently by 2 pathologists with specialization in gynecologic pathology. In addition, we were able to account for the smoking status of the study cohort. Slattery et al. (35) demonstrated that smoking significantly increases the risk of developing MSI in colorectal cancers. As such, it is plausible for smoking status to influence MSI status in endometrial carcinomas, although we did not detect an association. Finally, we were able to examine allcause deaths and endometrial cancer-related deaths separately in the survival analyses.
Our study also has limitations that should be considered. Our study cohort, although containing both white and African American women, was fairly small (n ¼ 76), which limits the power of this study. As noted earlier, no consensus exists as to what markers are best to determine MSI in endometrial cancers, and the percentage of MSI tumors is on the low end of what has been reported previously. It is possible that some tumors we classified as MSS using 10 markers would be classified as MSI if other markers were included. We also did not have access to full clinical data regarding treatment modality, which may have impacted our findings on the association between MSI and survival outcome. Thus, the findings of this study may be due to chance.
It is still unclear whether MSI is an independent predictor of survival after a diagnosis of endometrial cancer after adjusting for other known prognostic variables. Given that MSI has been shown to predict response to chemotherapy in colon cancers (36) , it is plausible that a similar association exists in endometrial cancer. It does seem that for type I cancers, more African American women had MSI tumors compared with white women. A larger prospective study with the power to stratify by race and stage, along with the ability to account for various factors such as histology, comorbid conditions, and treatment is warranted.
